Apulmiq’s Benefits Confirmed in Third-party Evaluation

Apulmiq’s Benefits Confirmed in Third-party Evaluation
A third-party evaluation (TPE) confirmed the efficacy of the bronchiectasis treatment candidate Apulmiq found in Phase 3 trials, Aradigm, the developer of the therapy, recently announced. Apulmiq, previously known as Linhaliq and Pulmaquin, is a liquid mixture of a slow-release form of liposomes — tiny phospholipid vesicles made of the same material (phospholipids) as the cell membrane — loaded with the antibiotic ciprofloxacin, a widely prescribed antibiotic for acute lung infections. The therapy acts primarily against the bacteria Pseudomonas aeruginosa, known to cause infections in about one-third of bronchiectasis patients, and associated with a lower quality of life, risk of  accelerated lung function deterioration, and more frequent exacerbations than other bacterial strains. In 2017, Aradigm submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for Apulmiq as a treatment for people with bronchiectasis and chronic Pseudomonas aeruginosa lung infections, based on positive data from the Phase 3 ORBIT-3 (NCT01515007) and ORBIT-4 (
Subscribe or log in to read the rest of this content.